Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 24;6(4):101016.
doi: 10.1016/j.jhepr.2024.101016. eCollection 2024 Apr.

Infections increase the risk of decompensation and death in patients with early alcohol-related liver disease

Collaborators, Affiliations

Infections increase the risk of decompensation and death in patients with early alcohol-related liver disease

Stine Johansen et al. JHEP Rep. .

Erratum in

Abstract

Background & aims: Infections are frequent in patients with cirrhosis and worsen prognosis. We evaluated the incidence of infections and their impact on decompensation and death in patients with early alcohol-related liver disease (ALD) during long-term follow-up.

Methods: We performed a prospective cohort study of patients in secondary care with a history of excess alcohol intake, no prior decompensation, and with liver biopsies along with clinical investigations conducted at baseline. During follow-up, we reviewed the patients' electronic healthcare records for cases of infections, hospitalizations, transient elastography measurements, decompensations, all-cause mortality, and alcohol intake.

Results: We included 461 patients with a mean age of 56±10 years (76% males; fibrosis stage F0-1/F2/F3-4 = 259/107/93 [56%/23%/20%]). During a median follow-up of 4.5 years (IQR 2.9-6.3), 134 patients (29%) developed a total of 312 infections, most frequently pneumonia (106/312, 34%) and urinary tract infections (57/312, 18%). Excessive alcohol intake during follow-up, smoking ≥30 pack years, MELD score and elevated liver stiffness during follow-up were independent predictors of infections. Patients who developed at least one infection had a significantly increased risk of subsequent decompensation (hazard ratio 4.98, 95% CI 2.47-10.03) and death (hazard ratio 8.24, 95% CI 4.65-14.59). Infections increased the risk of decompensation and death independently of baseline fibrosis stage, age, gender, and MELD score.

Conclusions: Almost one-third of patients with early ALD develop an infection, which worsens their prognosis by increasing the risk of decompensation and death. The risk of infections increases with liver disease severity and ongoing harmful use of alcohol.

Impact and implications: This study reveals that infections significantly worsen the prognosis of patients with early alcohol-related liver disease (ALD), increasing the likelihood of decompensation and death by up to eight times. These findings, pertinent to healthcare providers, researchers, and policymakers, emphasize the importance of early prevention and management of infections in patients with ALD, even those in early stages who may be asymptomatic. It was observed that nearly one-third of patients with early-stage ALD developed infections over 4.5 years, with risk factors including alcohol overuse, smoking, and higher MELD scores. The research underscores the critical need to incorporate these insights into clinical practice and public health policies to improve patient outcomes and mitigate the impact of infections in patients with ALD.

Keywords: Alcoholic liver disease; Cirrhosis; Decompensation; Fibrosis; Prognosis.

PubMed Disclaimer

Conflict of interest statement

MT: Speaker’s fee for Echosens, Siemens Healthcare, Norgine, Madrigal, Takeda, and Tillotts Pharma. Advisory fee from GE Healthcare, Boehringer Ingelheim, GSK and AstraZeneca. Co-founder and board member for Evido. Board member for Alcohol & Society (non-governmental organisation). AK has received grants from EU Horizon 2020, Novo Nordisk Foundation, Innovationfund Denmark, Danish National Research Foundation, Region of Southern Denmark, and AstraZeneca, receives royalties from Gyldendal as a co-author on a textbook of internal medicine, served as speaker for Novo Nordisk, Norgine, Siemens and Nordic Bioscience, and participated in advisory boards for Norgine, Siemens, Resalis Therapeutics, Boehringer Ingelheim and Novo Nordisk. Research support; Norgine, Siemens, Nordic Bioscience, AstraZeneca, Echosens. Consulting Takeda, Resalis Therapeutics, Zealand Pharma, AlphaSights. Board member and co-founder of Evido. JKH: Speaker’s fee from Norgine. MK: Speaker’s fee from Siemens Healthcare. SJ, SL, DNR, MI, KL, CDH, KT, NT, PA, USJ, SD, HBJ, and TH have nothing to disclose. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Cumulative incidence of infections and severe infections. (A) Cumulative incidence of infections. (B) Cumulative incidence of severe infections.
Fig. 2
Fig. 2
Risk of death and decompensation in patients developing infections. (A) Risk of death in patients developing infections (Simon & Makuch plot). (B) Risk of decompensation in patients developing infections (Simon & Makuch plot). Between-group comparisons for survival data with a time-dependent covariate was performed using the Mantel-Byar test.
Fig. 3
Fig. 3
Cumulative incidence of infections. (A) Cumulative incidence of infections stratified by Kleiner fibrosis stage. (B) Cumulative incidence of infections stratified by liver stiffness; The cumulative incidence plot is based on 447 patients as liver stiffness measurements are missing in 14 patients. (C) Cumulative incidence of infections stratified by excessive alcohol use during follow-up; The cumulative incidence plot is based on 403 patients as data on alcohol intake was not available in 58 patients.

References

    1. Alcohol G.B.D., Drug Use C. The global burden of disease attribuTable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012. - PMC - PubMed
    1. IHME Global Burden of disease. 2019. http://ghdx.healthdata.org/
    1. Piano S., Singh V., Caraceni P., et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology. 2019;156(5):1368–1380 e1310. - PubMed
    1. Arvaniti V., D'Amico G., Fede G., et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246–1256. 1256 e1241-1245. - PubMed
    1. Hagstrom H., Thiele M., Simon T.G., et al. Risk of infections and their role on subsequent mortality in biopsy-proven alcohol-related liver disease. United Eur Gastroenterol J. 2022;10(2):198–211. - PMC - PubMed

LinkOut - more resources